Additional file 1 of An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis

Additional file 1: Figure 1. Proportion of patients who did not have serum phosphorus data available or who did not satisfy other eligibility criteriaa after 8 weeks of CC followed by 8 weeks of LC (A) and after at least 8 weeks of LC (B); these patients were thus excluded from the efficacy analyses (per-protocol sets 1 and 2).